Welcome to our dedicated page for Senzime Ab news (Ticker: SNZZF), a resource for investors and traders seeking the latest updates and insights on Senzime Ab stock.
Senzime AB reports recurring developments around its TetraGraph neuromuscular monitoring system, hospital contracting in the United States, and commercialization through integrated delivery networks and group purchasing organizations. Company updates also cover TetraCom connectivity, financial reports, margin and cash-flow commentary, and expansion of U.S. sales, clinical, and medical-affairs functions.
Governance-related announcements include annual general meeting notices and shareholder-program proposals, while operating updates focus on anesthesia data transmission, hospital procurement access, system installations, and recurring revenue tied to the installed base.
Senzime (OTCQX:SNZZF) launched TetraAnalytics, a cloud-based data analytics platform that extends the TetraGraph neuromuscular monitoring system. The platform automates data analysis, tracks protocol and guideline alignment, uses the Train-of-Four Quality Indicator (TQi), and supports advanced visualization and remote analytics for perioperative care improvement.
Senzime will showcase TetraAnalytics, the next-generation TetraGraph system and the new TetraSens EMG sensor at Euroanaesthesia 2026 in Rotterdam and sponsor a lunch symposium on neuromuscular monitoring advances.
Senzime (OTCQX:SNZZF) reported progress in pediatric anesthesia, winning a new contract from a top-ranked pediatric hospital in the Eastern U.S. to equip all operating rooms with TetraGraph systems after competitive evaluation.
New pediatric research shows reduced respiratory complications and cost savings with quantitative neuromuscular monitoring.
Senzime (OTCQX:SNZZF) has launched its latest TetraSens EMG sensor for the TetraGraph Train-of-Four neuromuscular monitoring system. The sensor is commercially available in Europe and is planned for U.S. introduction in Q3 2026.
The new design uses 50% less dielectric material than legacy sensors while maintaining existing performance specifications. It is manufactured in Europe with an environmentally focused process, regional supply chain, shorter transport routes and smart packaging. The sensor adds visual guidance for faster, more consistent placement and is protected by EU and U.S. patents.
Senzime (OTCQX:SNZZF) has received an additional FDA Class II 510(k) clearance for its TetraGraph neuromuscular monitoring system, following an April 2026 submission.
The clearance expands the system’s capabilities and supports next-generation features. TetraGraph is used in over 750 hospitals to help anesthesiologists optimize intubation, drug dosing, and extubation decisions.
The annual general meeting of Senzime (OTCQX:SNZZF, STO:SEZI) on 19 May 2026 approved the 2025 accounts, carried forward results and decided that no dividend will be paid. The board and CEO were discharged from liability and board/auditor fees were set.
Shareholders adopted Board Program 2026 with share rights and authorized up to 700,000 Class C shares to service it, approved Employee Stock Option Program 2026/2030 for up to 2,640,000 options, introduced Class C shares in updated articles, re-elected most directors, elected one new director, and renewed the mandate to increase share capital by up to 15% via new equity instruments.
Senzime (OTCQX:SNZZF) announced senior U.S. leadership changes to strengthen commercial and clinical operations. Josi Wood joins as Vice President of U.S. Sales on May 11, 2026, and Jen Sanders is promoted to Vice President of Clinical and Medical Affairs effective May 1, 2026. G.W. Hamilton moves from President of Senzime Inc. to General Manager of U.S. operations.
The appointments aim to scale U.S. commercial execution and deepen clinical leadership as Senzime advances its perioperative patient-safety offerings.
Senzime (OTCQX:SNZZF) announced that its TetraGraph System was added to agreements with Vizient, Premier, and HealthTrust Performance Group on April 24, 2026. These three GPOs serve roughly 95% of US hospitals and have combined annual purchasing volumes exceeding USD 200 billion. The company said GPO listings remove procurement barriers, may shorten sales cycles with pre-negotiated pricing, and could help convert pipeline opportunities into orders, supporting broader US commercial expansion over time.
Senzime (OTCQX:SNZZF / STO:SEZI) published its 2025 annual and sustainability report on April 24, 2026, available on the company website.
The company reports it exceeded SEK 100 million in sales, increased growth rate, met its sales growth targets in constant currencies, kept costs according to plan, secured several strategic wins, and says it laid the foundation for profitability in 2026.
Senzime (OTCQX:SNZZF) reported Q1 2026 results: net sales SEK 23,233k (‑1%; currency‑adjusted +11%), gross margin 63.1%, operating expenses SEK 35,562k and operating loss before depreciation SEK -20,202k. Profit after financial items was SEK -23,242k and EPS -0.14 SEK.
Cash and cash equivalents were SEK 55,353k with an unused credit facility of SEK 42,500k. Cash flow improved by 33% (SEK 12.7m). Management says US timing shifts temporarily slowed growth but full‑year 2026 targets and profitability guidance remain on track.
Senzime (OTCQX:SNZZF) announced on April 20, 2026 an expanded contract with a leading southeastern US hospital system for an additional 65 TetraGraph systems.
The network will now have over 160 TetraGraph installations, generating an estimated annual recurring revenue > SEK 6 million. Senzime has delivered more than 5,000 TetraGraphs and its solutions are used in over 750 hospitals.